SCHEMBL5023009

SCHEMBL5023009

COc1ccc(CCNc2cc(-c3nccs3)nc(-c3ccco3)n2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
TSHR P16473 1/20 0.51
ADORA2A P29274 6/20 0.51
ADORA1 P30542 4/20 0.51
ADORA3 P0DMS8 3/20 0.51
ADORA2B P29275 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 3/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 2/20 0.47
PTGDR Q13258 2/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5025068 0.93 MAPT (0.56) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL5016281 0.85 ADORA2A (0.60) MAPTADORA2AADORA1ADORA3ADORA2B
SCHEMBL4504504 0.78 TSHR (0.64) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL8286672 0.77 SMN1; SMN2 (0.46) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL5016173 0.77 ADORA2A (0.55) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL5022257 0.77 ADORA2A (0.55) TSHRADORA2AADORA1ADORA3ADORA2B
SCHEMBL5016171 0.76 ADORA2A (0.60) ADORA2AADORA1ADORA3ADORA2BKDM4E
SCHEMBL6038244 0.76 ADORA2A (0.45) MAPTTSHRADORA2AADORA1ADORA3
SCHEMBL5022246 0.74 ADORA2A (0.47) MAPTCYP1A2CYP2C9CYP2C19TSHR
SCHEMBL5024974 0.74 ADORA2A (0.56) ADORA2AADORA1ADORA3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 MAPT 1877/4885CYP1A2 307/4885CYP3A4 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.